AR089710A1 - Composiciones farmaceuticas estabilizadas de un inhibidor del virus de hepatitis c - Google Patents

Composiciones farmaceuticas estabilizadas de un inhibidor del virus de hepatitis c

Info

Publication number
AR089710A1
AR089710A1 ARP130100099A ARP130100099A AR089710A1 AR 089710 A1 AR089710 A1 AR 089710A1 AR P130100099 A ARP130100099 A AR P130100099A AR P130100099 A ARP130100099 A AR P130100099A AR 089710 A1 AR089710 A1 AR 089710A1
Authority
AR
Argentina
Prior art keywords
hepatitis
pharmaceutical compositions
stabilized pharmaceutical
virus inhibitor
compound
Prior art date
Application number
ARP130100099A
Other languages
English (en)
Spanish (es)
Inventor
Alan Busacca Carl
Chen Feng
Jing-Gump Edwin
B Majeska Jenness
Pennino Scott
Qiu Fenghe
Fernanda Villagra Maria
Braun Mathias
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089710(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR089710A1 publication Critical patent/AR089710A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP130100099A 2012-01-12 2013-01-11 Composiciones farmaceuticas estabilizadas de un inhibidor del virus de hepatitis c AR089710A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261586087P 2012-01-12 2012-01-12

Publications (1)

Publication Number Publication Date
AR089710A1 true AR089710A1 (es) 2014-09-10

Family

ID=47628447

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100099A AR089710A1 (es) 2012-01-12 2013-01-11 Composiciones farmaceuticas estabilizadas de un inhibidor del virus de hepatitis c

Country Status (27)

Country Link
US (2) US20140037719A1 (index.php)
EP (1) EP2802313A1 (index.php)
JP (1) JP2015503616A (index.php)
KR (1) KR20140109433A (index.php)
CN (1) CN104244926A (index.php)
AP (1) AP2014007760A0 (index.php)
AR (1) AR089710A1 (index.php)
AU (1) AU2013208024A1 (index.php)
BR (1) BR112014017058A8 (index.php)
CA (1) CA2861041A1 (index.php)
CL (1) CL2014001783A1 (index.php)
CO (1) CO7000774A2 (index.php)
EA (1) EA201400808A1 (index.php)
EC (1) ECSP14013104A (index.php)
HK (1) HK1204982A1 (index.php)
IL (1) IL233550A0 (index.php)
IN (1) IN2014DN05759A (index.php)
MA (1) MA35865B1 (index.php)
MX (1) MX2014008205A (index.php)
NZ (1) NZ626353A (index.php)
PE (1) PE20141817A1 (index.php)
PH (1) PH12014501598A1 (index.php)
SG (1) SG11201404042VA (index.php)
TN (1) TN2014000295A1 (index.php)
TW (1) TW201340969A (index.php)
UY (1) UY34569A (index.php)
WO (1) WO2013106506A1 (index.php)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2014145095A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis c virus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5329976A (en) * 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
EP1654261B1 (en) 2003-05-21 2007-11-14 Boehringer Ingelheim International GmbH Hepatitis c inhibitor compounds
US7514557B2 (en) 2004-05-25 2009-04-07 Boehringer Ingelheim International Gmbh Process for preparing acyclic HCV protease inhibitors
WO2006130552A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
MY153093A (en) 2008-09-16 2014-12-31 Boehringer Ingelheim Int Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor
UA105777C2 (uk) * 2008-11-21 2014-06-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Фармацевтична композиція ефективного інгібітора вгс для перорального введення
KR101685941B1 (ko) 2009-07-07 2016-12-13 베링거 인겔하임 인터내셔날 게엠베하 C형 간염 바이러스 프로테아제 억제제를 위한 약제학적 조성물

Also Published As

Publication number Publication date
PH12014501598A1 (en) 2014-10-08
BR112014017058A2 (pt) 2017-06-13
BR112014017058A8 (pt) 2017-07-04
CN104244926A (zh) 2014-12-24
US20140037719A1 (en) 2014-02-06
JP2015503616A (ja) 2015-02-02
AU2013208024A1 (en) 2014-07-10
US20150190458A1 (en) 2015-07-09
CO7000774A2 (es) 2014-07-21
EP2802313A1 (en) 2014-11-19
AP2014007760A0 (en) 2014-07-31
IN2014DN05759A (index.php) 2015-04-10
UY34569A (es) 2013-07-31
KR20140109433A (ko) 2014-09-15
CA2861041A1 (en) 2013-07-18
SG11201404042VA (en) 2014-08-28
MX2014008205A (es) 2014-08-08
NZ626353A (en) 2016-02-26
CL2014001783A1 (es) 2014-12-12
EA201400808A1 (ru) 2015-02-27
TW201340969A (zh) 2013-10-16
PE20141817A1 (es) 2014-12-17
HK1204982A1 (en) 2015-12-11
ECSP14013104A (es) 2015-11-30
MA35865B1 (fr) 2014-12-01
TN2014000295A1 (en) 2015-12-21
IL233550A0 (en) 2014-08-31
WO2013106506A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
EA201590457A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
NI201600098A (es) Composiciones farmacéuticas que comprenden azd9291
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
NZ703064A (en) Inhibitors of hepatitis c virus
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
IL232267A (en) Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
EA201291410A1 (ru) Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
MX345238B (es) (aralquilamino y heteroarilalquilamino alfa-substituidos)pirimidin ilo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
GEAP201914546A (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
RU2009138047A (ru) Стабилизация витамина в12
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
AR089710A1 (es) Composiciones farmaceuticas estabilizadas de un inhibidor del virus de hepatitis c
AR083780A1 (es) Composicion farmaceutica para tratar infecciones del hcv
AR134057A2 (es) Composición farmacéutica en solución acuosa
ME02285B (me) Farmaceutska jedinjenja koja sadrže beta galaktozidazu i alfa galaktozidazu i njihova upotreba za lečenje bolesti gastroezofagealnog refluksa

Legal Events

Date Code Title Description
FB Suspension of granting procedure